Fidelity SPDR Advertisement
Home > Boards > Free Zone > Health and Sciences > Biotech Values

>AVEOwhether they would rather focus on other indications

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
biomaven0 Member Profile
Member Level 
Followed By 62
Posts 3,735
Boards Moderated 0
Alias Born 02/27/07
160x600 placeholder
How to Find a Missing Tax Refund
What ever happened to my missing federal income-tax refund check?
European Markets Show Signs of Stress--2nd Update
Microsoft Gains Help Lead Tech's Advance
Treasury Bonds Pull Back for Second Straight Day
Will Free Data Become the Next Free Shipping?
Microsoft Braces for Another Nokia Hit--Earnings Preview
Procter & Gamble Looking at Margins, Brands--Earnings Preview
Pfizer Results Will Play Second Fiddle to Dealmaking Outlook -- Earnings Preview
Stifel Financial to Hire Two Former Merrill Lynch Advisers
U.S. Stocks Gain, but IBM Weighs on Dow
biomaven0 Member Level  Thursday, 09/08/11 09:41:43 AM
Re: NP1986 post# 126293
Post # of 183196 
>AVEO

Quote:
whether they would rather focus on other indications



My guess is they will try to go for combination therapy - any place where Avastin has shown good results in combination would be a good place to start.

In terms of going up against Sutent vs. against Nexavar, it's somewhat instructive that Pfizer made the same choice in 2nd line for their drug. I'm of the view that a small company should almost always take the easiest path to registration - worry about expanding the market once you have approval.

Peter

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist